Previous 10 | Next 10 |
IMV IMV -20% on $25M capital raiseGalapagos GLPG -12% topline results from early-stage GLPG3667 psoriasis studyPop Culture (CPOP) -8%.Yunhong CTI (CTIB) -7%.Tempest Therapeutics (TPST) -7%.U.S. Energy (USEG) -7%.Exela Technologies (XELA) -6%.Oxbridge Re Holdings (OXBR) -6%...
Galapagos (GLPG) announces positive topline results with tyrosine kinase 2 ((TYK2)) inhibitor GLPG3667 in an early-stage study in psoriasis patients.The trial was a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psor...
Biologic effect of salt inducible kinase ( SIK ) mechanism in first patient studies supports further progression of Toledo portf olio SIK2/3 inhibitor GLPG39 70 generally safe and well - tolerated ...
Generally safe and well tolerated Positive efficacy signal in psoriasis patients at We ek 4 40% of patients showed improvement of at least 50 % in PASI response (PASI 50) with high dose of GLPG3667 at Week 4 ...
designer491/iStock via Getty Images Galapagos (GLPG) announces new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib for the treatment of patients with moderately to severely active ulcerative colitis ((UC)). A post-hoc analysis showe...
New post-hoc analys es of data from SELECTION P hase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress Mechelen , Belgium; 10 July 2021, 11 . 1 0 CET; Galapagos NV (Eu...
Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales in Europe in the medium term. The partnership with biotech giant Gilead dem...
Mechelen, Belgium; 22 June 202 1 , 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year . Dr. Piet Wigerinck joined Galapagos as Senior Vic...
Results from Galapagos' (GLPG) Phase 3 SELECTION induction and maintenance study were published in The Lancet.The study, sponsored by Gilead Sciences (GILD) was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation...
Mechelen, Belgium ; 4 June 2021 ; 07 . 01 CET ; – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that primary and secondary endpoint results from the phase 3 SELECTION induction and maintenance study (NCT029145...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...